Modulation of complement activation on hemodialysis membranes by immobilized heparin.
To determine the effects of surface-associated heparin on the capacity of hemodialysis membranes to activate complement, cellulose acetate (CA) membranes that were untreated and CA membranes that had been coated with heparin (HCA) were incubated with C3-depleted serum repleted with radio-labeled C3. Next, the proteins in the supernatant and those eluted from the membranes were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis. C3 activation was quantified by determining the radioactivity of the C3a-containing band in the gel. Total C3a generation (fluid phase C3a plus membrane-associated C3a) was three times greater in the presence of HCA compared with CA. Most (88%) of the C3a generated in the presence of HCA, however, was adsorbed onto the membrane surface. Consequently, there was more C3a in the CA supernatant than in the HCA supernatant. To determine the mechanism by which heparin enhanced alternative pathway activity, binding studies with radiolabeled factor B and factor H were performed. HCA bound 3.4 times more factor B and 20 times more factor H than did CA. The binding of these proteins, however, was not dependent on complement activation. Studies designed to test the functional activity of isolated factor H and factor B that had been adsorbed to the membrane showed that factor H was active on both CA and HCA, whereas factor B was active only on HCA. These data demonstrate that heparin immobilized onto CA hemodialysis membrane enhances C3 activation but produces low levels of C3a in the fluid phase because of high surface adsorption of the anaphylatoxin. Heparin appears to augment alternative pathway activity by favoring the interactions of factor B with other constituents of the amplification C3 convertase of the alternative pathway of complement.
Cheung
A K
AK
Department of Medicine, University of Utah School of Medicine, Salt Lake City.
Parker
C J
CJ
Janatova
J
J
Brynda
E
E
D001672:Biocompatible Materials; D002482:Cellulose / Q000031:analogs & derivatives; D003176:Complement C3 / Q000032:analysis; D015926:Complement C3a / Q000032:analysis; D003180:Complement C3b Inactivator Proteins / Q000502:physiology; D011415:Complement Factor B / Q000502:physiology; D017242:Complement Factor H; D003170:Complement Pathway, Alternative / Q000187:drug effects* / Q000502:physiology; D006493:Heparin / Q000494:pharmacology*; D006801:Humans; D008567:Membranes, Artificial; D006435:Renal Dialysis / Q000295:instrumentation*
D001672:Biocompatible Materials; C493495:CFH protein, human; D003176:Complement C3; D003180:Complement C3b Inactivator Proteins; D008567:Membranes, Artificial; C005062:acetylcellulose; D015926:Complement C3a; D017242:Complement Factor H; D002482:Cellulose; D006493:Heparin; D011415:Complement Factor B